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Abstract Lung ultrasound (LUS) is a valid tool for the
assessment of heart failure (HF) through the quantification of
the B-lines. This study in HF patients aims to evaluate if
LUS: (1) can accelerate the discharge time; (2) can efficiently
drive diuretic therapy dosage; and (3) may have better per-
formance compared to the amino-terminal portion of B type
natriuretic peptide (NT-proBNP) levels in monitoring HF
recovery. A consecutive sample of 120 HF patients was
admitted from the Emergency Department (ED) to the
Internal Medicine Department (Verona University Hospital).
The Chest X-ray (CXR) group underwent standard CXR
examination on admission and discharge. The LUS group
underwent LUS on admission, 24, 48 and 72 h later, and on
discharge. The Inferior Cava Vein Collapsibility Index,
ICVCI, and the NT-proBNP were assessed. LUS discharge
time was significantly shorter if compared to CXR group
(p\0.01). During hospitalization, the LUS group underwent
an increased number of diuretic dosage modulations com-
pared to the CXR group (p\0.001). There was a stronger
association between partial pressure of oxygen in arterial
blood (PaO2) and B-lines compared to the association
between PaO2 and NT-proBNP both on admission and on
discharge (p\0.001). The B-lines numbers were signifi-
cantly higher on admission in patients with more severe HF,
and the ICVCI was inversely associated with B-lines number
(p\0.001). The potential of LUS in tailoring diuretic ther-
apy and accelerating the discharge time in HF patients is
confirmed. Until the technique comes into common use in
different departments, it is plausible that LUS will evolve
with different facets.
Keywords Lung ultrasound (LUS)  Heart failure (HF) 
Internal medicine  Discharge time
Abbreviations
CXR Chest X-ray
HF Heart failure
HFpEF Heart failure with preserved ejection fraction
HFmrEF Heart failure with mid-range ejection fraction
HFrEF Heart failure with reduced ejection fraction
ICVCI Inferior Cave Vein Collassability index
LUS Lung ultrasound
NT-pro
BNP
Circulating N-terminal pro-hormone of brain
natriuretic peptide
NYHA New York Heart Association
Introduction
Recently, lung ultrasound (LUS) has emerged in different
clinical settings [1–5] for the evaluation of patients with
acute respiratory failure. In particular, the main fields of
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LUS applications are: pneumothorax (PNX), interstitial
syndrome, lung consolidation and pleural effusion [6–8].
Heart failure (HF) is a clinical syndrome characterized
by typical symptoms and signs caused by structural or
functional cardiac abnormalities, resulting in a reduced
cardiac output or elevated intra-cardiac pressures at rest or
during stress [9].
The prevalence of HF is approximately 1–2% of the
adult population in developed countries, rising to C10%
among people[70 years of age, and it is the leading cause
of hospitalization [10].
LUS has been demonstrated to be a valid tool for the
assessment of pulmonary congestion [11–13] through the
quantification of the B-lines. B-lines are defined as laser-
like vertical hyperechoic reverberation artifacts that
emerge from the pleural line (previously defined as
‘‘comet tails’’ or ‘‘ring-downs.’’). Multiple B-lines are
the sonographic sign of lung interstitial syndrome. Their
number increases along with decreasing air content and
increase in lung density [4, 14]. Clearing of B-lines
significantly correlates with improved clinical symptoms
and signs of HF. B-lines due to cardiogenic pulmonary
edema are usually bilateral, and usually spread or
recover symmetrically [4]. Their regular distribution
allows differentiation between cardiogenic pulmonary
edema, acute respiratory distress syndrome (ARDS) and
pulmonary fibrosis [4, 14].
The plasma concentration of natriuretic peptides (NPs)
can be used as an initial HF diagnostic test, especially in
the setting of dyspnoea of unclear etiology. Elevated NPs
help to establish an initial working diagnosis. They are
considered predictors of prognosis of HF, and are used to
dictate the intensity of the diuretic therapy [15, 16].
Our previous studies [17–19] strongly support the daily
use of point of care ultrasound in Internal Medicine.
This study goes further.
The main objectives of this study are: (1) to test if LUS
use can speed up the discharge time in HF patients; (2) to
test if LUS can efficiently drive diuretic therapy dosage; (3)
to compare the performance of LUS and of the amino-
terminal portion of B type natriuretic peptide (NT-proBNP)
levels in monitoring HF recovery.
Materials and methods
Ethics statement
The study was conducted in accordance with the ethical
standards laid down in the Helsinki Declaration of 1975
and its late amendments. Informed consent was obtained
from all individual participants included in the study.
Study setting and population
The study setting was the Internal Medicine department of
the University Hospital of Verona, Italy, already certified
as a first level ultrasound centre by the Societa` Italiana di
Medicina Interna (SIMI).
The authors studied a consecutive sample of 120
patients (aged 70–94). They were admitted from the ED to
the Internal Medicine Department of the University
Hospital of Verona with the clinical diagnosis of HF.
Exclusion criteria were: concomitant acute coronary syn-
drome, pneumonia, chronic obstructive pulmonary disease,
lung cancer or metastases, lung fibrosis, previous pneu-
monectomy or lobectomy, breast prothesis, obesity, also in
order to avoid the detection of B-lines other than due to HF.
The study was conducted in winter 2016–2017 and
spring 2017.
Patients were classified according to the New York
Heart Association (NYHA) classes [20].The NYHA func-
tional classification was used to describe the severity of
symptoms and exercise intolerance at admission. HF was
classified according to the recent guidelines of the Euro-
pean Society of Cardiology [9]: patients with normal left
ventricular ejection fraction (LVEF) (C50%, HF with
preserved EF, HFpEF), patients with reduced LVEF
(\40%, HF with reduced EF, HFrEF), patients with an
LVEF in the range of 40–49% (HFmrEF).
Description of the study protocol
Patients were randomly allocated into two groups: the
Chest X-ray group (CXR) and the LUS group.
The CXR group underwent a standard CXR examination
on admission and on discharge.
The LUS group underwent LUS on admission, 24, 48
and 72 h later, and on discharge.
Trans-thoracic echocardiography at rest was performed
in all patients in order to classify the LVEF on admission.
Trans-thoracic echocardiography was performed by an
Internal Medicine specialist (CM) and a colleague (MDDP)
(they were certified by the Societa‘ Italiana di Ecografia
Cardiovascolare, SIEC). LUS examinations were performed
by CM, who was certified by the Societa` Italiana di Ultra-
sonologia in Medicina e Biologia (SIUMB). All LUS exam-
inations were performed by a single operator (CM) in order to
reduce the interobserver variability in the B-lines counting.
All ultrasound examinations were performed using an
EnVisor C HD Philips. The sector probe (2.5–3.5 MHz)
was the first choice of use for LUS examination (the con-
vex and the linear ones were also available). LUS exami-
nations were performed with patients in the supine or near-
supine position for the anterior scanning, and in the sitting
position for the dorsal scanning. A B-lines score, defined as
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the total number of the detectable B-lines, was determined,
according to the approach proposed by Gargani and
Volpicelli [4, 21].
Inferior cava vein (ICV) maximum and minimum
diameter and its collapsibility index (Inferior Cava Vein
Collapsibility Index, ICVCI) were measured in subcostal
view in M-mode, 2 cm from the right atrial junction in the
LUS group. ICVCI was calculated according to the formula
[(ICVmax - ICVmin)/ICVmax] 9 100. These measurements
were obtained using a convex transducer. The ICVCI %
cutoffs were: [75 (hypovolemia), C40 and B75 (euv-
olemia) and\40 (hypervolemia).
NT-proBNP dosage was obtained from peripheral
venous blood samples (Immunochemistry Analyzer,
COBAS 6000) in the LUS group on admission and on
discharge. Urine output and diuretic dosage were carefully
reported daily. Arterial blood samples were collected on
admission and on discharge in both groups to test the
partial pressure of oxygen (PaO2) as indicator of HF
severity (on admission) and recovery (on discharge).
Statistical analysis
Categorical and continuous characteristics at admission are
summarized as percentages and means with standard
deviations, respectively. Differences in the distribution of
the baseline characteristics between CXR and LUS groups
were tested using Chi squared test, Student’s T test, or
Mann–Whitney’s U test, as appropriate.
A quantile regression model was adopted to test the
difference in the number of days of hospitalizations from
admission to discharge in CXR group vs LUS group, using
a stepwise forward approach (with p\ 0.20 for entry and
p C 0.25 for removal) for selecting the variables to include
in the multivariate model.
The correlations of number of the B-lines and NT-pro-
BNP, opportunely log-transformed to achieve normal dis-
tribution, with PaO2 and ICVCI were evaluated using lin-
ear regression models using the data on admission and on
discharge, taking into account intra-subject variability
using cluster-robust standard errors.
The velocity of clearance of log(number of the B-lines)
at 0, 24, 48, and 72 h after admission according to HF
severity was evaluated using an two-way ANOVA model,
with time-dependent repeated measures.
Statistical analyses were performed using STATA 14.2.
Results
The baseline demographic and clinical characteristics of
the patients on admission are reported in Table 1. All
patients were classified in NYHA IV class.
Drug therapy was similar in the CXR and LUS groups
(angiotensin-converting enzyme inhibitors, b-blockers,
statins, anticoagulant/anti-platelets drugs) except for
diuretics (more frequent in the LUS group). The subjects
included in the LUS group had lower PaO2 at admission
compared to those included in the CXR group (mean: 62.9
vs 70.3, p\ 0.001); the calculated ratio of arterial oxygen
partial pressure to fractional inspired oxygen (PaO2/FiO2
ratio) was, respectively, 299.52 vs 334.76, FiO2 0.21 (21%,
without oxygen supply).
The average time required to acquire and interpret LUS
was 7 ± 1 min.
Figure 1 shows the discharge time (measured as hospi-
talization days) for the CXR and the LUS groups.
LUS discharge time was significantly shorter if com-
pared to the CXR group: median (range) CXR: 8 (4–17);
LUS 7 (3–10), p value for difference: p\ 0.001.
In the stepwise multivariate regression model, LUS
discharge time was significantly shorter if compared to
CXR group (coefficient: -1.812, 95% CI -2.719, -0.906;
p\ 0.001). The PaO2 on admission was also significantly
associated with discharge time, with higher PaO2 levels
associated with shorter hospital stay (coefficient: -0.063;
95% CI -0.107, -0.018; p = 0.006). The use of diuretics
was also included in the final stepwise model with the
above two variables, but its association with time to dis-
charge did not reach statistical significance (coefficient:
0.688; 95% CI -0.166, 1.541; p = 0.113).
During hospitalization, the LUS group underwent an
increased number of diuretic dosage modulations com-
pared to the CXR group (p\ 0.01). In the CXR group,
33% (20 out of 60) of the patients, had a single diuretic
modulation, while 67% (40 out of 60) had two; on the other
hand, none of the patients in the LUS group had only one
diuretic modulation, 12% had two modulations (7 out of
60), and 88% (53 out of 60) had three.
Figure 2 shows the associations of PaO2 and the B-lines
on admission and discharge and PaO2 and NT-proBNP on
admission and discharge (both expressed in log10). The
B-lines are strongly associated with the levels of PaO2, as
log10 (B-lines) predicted 33% of the variability of PaO2
(r2 = 0.331; p\ 0.001). On the other hand, the associa-
tion between NT-proBNP and PaO2 is weaker, with log10
(B-lines) predicting only 1% of the PaO2 variability
(r2 = 0.012; p = 0.034).
The number of the B-lines was significantly higher on
admission in patients with more severe HF.(p\ 0.01)
(Fig. 3). Overall the B-lines diminished of -23, -39, and
-50% after 24, 48, and 72 h, respectively, compared to the
number of the B-lines on admission. There was no inter-
action between time and severity of HF (p = 0.866). This
indicates that, despite the velocity of clearance in absolute
numbers was quicker in the groups with higher B-lines on
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admission, the relative velocity in B-lines clearance was
similar across the three groups of HF severity.
The ICVCI was measured on admission and discharge in
the LUS group. There is an inverse significant association
between this index and the number of B-lines (p\ 0.01),
as shown in Fig. 4.
PaO2 (mmHg) on discharge was 98 ± 1 for both groups
without oxygen supply.
Discussion
LUS is becoming a standard tool in critical care for the
early diagnosis of acute respiratory failure [21]. The ‘‘de-
cision tree’’ used to guide this diagnosis is the well-known
bedside lung ultrasound evaluation (BLUE) protocol [22].
The advantage of this protocol is its rapidity.
Moreover, LUS is not only a simple approach to dis-
criminating among its main fields of application [6, 7];
LUS can be also used as a monitoring tool in HF patients.
Different studies [13, 23–25] have been designed in
different settings other than Emergency settings. They have
been designed to define the performance of LUS compared
to clinical assessment, to NPs levels and to traditional CXR
in HF patients, both outpatients and inpatients. These
studies have confirmed that the B-lines are prognostic
markers for hospital re-admission or death in HF patients.
Moreover, the prognostic value of LUS is confirmed
independently of the method used to evaluate the B-lines
Table 1 Demographic
characteristics at baseline/
admission of the enrolled
patients
CXR group (n = 60) LUS group (n = 60) p value
Age (years) 83.7 (0.9) 83.8 (0.9) 0.970
Gender (females) 38 (63%) 37 (62%) 0.850
Ejection fraction
Preserved 28 (47%) 22 (37%) 0.009
Mid-range 10 (17%) 25 (42%)
Reduced 22 (37%) 13 (22%)
Ischemic heart disease 24 (40%) 25 (42%) 0.853
Valvular heart disease 19 (32%) 25 (42%) 0.256
Type 2 diabetes mellitus 17 (28%) 21 (35%) 0.432
SBP (mmHg) 137.8 (2.7) 131.8 (2.8) 0.126
DBP (mmHg) 74.4 (1.5) 72.3 (1.3) 0.245
Heart rate (beats/min) 82.2 (2.2) 87.5 (2.2) 0.096
Creatinine (mg/dL) 1.30 (0.07) 1.35 (0.08) 0.640
Therapy (on admission)
Ace-inhibitors 28 (47%) 29 (48%) 0.855
b-blockers 42 (70%) 38 (63%) 0.439
Diuretics 40 (67%) 51 (85%) 0.019
Statins 29 (48%) 29 (48%) 1.000
Anti-coagulants 21 (35%) 27 (45%) 0.264
Anti-aggregants 30 (50%) 25 (42%) 0.360
PaO2 (mmHg) 70.3 (1.3) 62.9 (1.1) \0.001
Data are expressed in n (%) or mean standard deviation (SD)
CXR chest X-ray, DBP diastolic blood pressure, HF heart failure, HFpEF heart failure with preserved
ejection fraction, HFmfEF heart failure with mid-range ejection fraction, HFrEF heart failure with reduced
ejection fraction, LUS lung ultrasound, NT-pro-BNP N-terminal fragment brain natriuretic peptides, PaO2
partial pressure of oxygen in arterial blood, SBP systolic blood pressure
Fig. 1 Discharge time (measured as hospitalization days) for the
CXR and the LUS groups. CXR chest X-ray, LUS lung ultrasound
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burden (semi-quantitative, 8 zones, 28 zones, 72 zones),
allowing a prognostic risk stratification on discharge. They
provide an important step forward for the implementation
of LUS in the clinical evaluation of HF patients.
It is well known that the costs associated with HF hos-
pitalization are consistent in Internal Medicine, with
increased hospital stay days [26, 27]. Moreover, these costs
are compounded by a high rate of re-admission.
In this context, the main finding of this study is that LUS
speeds up the discharge time in HF patients, and that
congestive failure is one of the most common admission
diagnosis in the Internal Medicine Department. This result
may be due to different reasons. The LUS operator is not
blinded to the patients’ clinical conditions (while the
Radiologist usually has only an information summary
about them). Furthermore, the possibility of performing
LUS bedside at any moment allows for an easier man-
agement of the therapy. In fact, in this study, the LUS
group underwent an increased number of diuretic dosage
modulations compared to the CXR group. Remarkably, the
LUS group discharge time was shorter although with a
lower PaO2 on admission. We have no precise explanation
about this point because patients were randomly allocated
Fig. 2 The associations
between PaO2 and B-lines on
admission and discharge (on the
left), and PaO2 and NT-pro-
BNP on admission and
discharge (on the right) in the
LUS group. PaO2 partial
pressure of oxygen in arterial
blood (mmHg), NT-pro-BNP
N-terminal fragment brain
natriuretic peptides, LUS lung
ultrasound, black dots
admission; white dots discharge;
p\ 0.001
Fig. 3 Severity of heart failure measured by echocardiography and
the B-lines clearance time (hours). D discharge time, HFpEF heart
failure with preserved ejection fraction, HFmfEF heart failure with
mid-range ejection fraction, HFrEF heart failure with reduced
ejection fraction
Fig. 4 The association between the ICVCI and the B-lines on
admission and discharge in the LUS group. ICVCI Inferior Cave Vein
Collapsibility Index; black square admission, white squares dis-
charge; p value\0.001
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to the LUS or to the CXR group. This fact reinforces the
ability of LUS in speeding up the discharge time also in
patients with more severe conditions at baseline.
The second important result of this study concerns the
B-lines and their role in monitoring HF recovery. The
results of this study show a stronger association between
PaO2 and B-lines compared to the association between
PaO2 and NT-proBNP both on admission and on discharge.
The B-lines are not mentioned in HF ESC guidelines
[9]. In this study, the reduction of the B-lines does not
occur in accordance with the NT-proBNP levels, suggest-
ing that serum NT-proBNP may not reliably indicate pul-
monary congestion having been resolved. These results
lead us to consider this molecule a useful marker for the
discrimination of the possible origin of respiratory failure,
but it is not so precise in monitoring HF recovery. NT-pro-
BNP has proved to be effective only in excluding or con-
firming congestive HF. These data support the use of this
molecule in the Critical care setting rather than in the
Internal Medicine Department. Moreover, it has been
established that NPs levels are affected by age, as known,
[28] or by other conditions such as body mass index [29],
myocardial ischemia and hypoxia even in the absence of
left ventricular dysfunction [30], hormonal dysfunctions
[31], renal failure and diabetes [32]. In this study, age is
probably the major confounder in the evaluation of NT-
pro-BNP levels.
The B-lines clearance time is longer in patients with
HFrEF compared to those with HFpEF and HfmrEF. This
result underlines the importance of a combined approach
(ecocardiography and LUS). This fact is confirmed also by
the importance of the ICVCI evaluation. In fact, the ICVCI
was computed on admission and on discharge in the LUS
group and a significant association between this index and
the number of the B-lines is found.
Nevertheless, this study has several limitations: the
sample is composed of elderly people so it is arguable that
the acoustic window could be affected by the patient
positioning (effort of maintaining the correct position both
the supine and the sitting one).
Also the method of quantification of the B-lines could be
a source of disagreement. Scan techniques can be broadly
divided into two groups: the scanning modality by zones or
the scanning modality by fixed points, as described in
Methods section. The authors counted the total number of
the detectable B-lines in anterolateral and posterior scan-
ning sites. This protocol is well established [4, 21]; nev-
ertheless, this evaluation could be even excessively
accurate, taking too much time.
The context makes the difference. The Internal Medi-
cine Department can spend more time on the patients’
clinical examination compared to the emergency one.
It has to be recognized that the LUS technique in the
B-lines identification and counting is not fully standardized
and many issues against LUS in HF exist, in particular
because of the low specificity of the B-lines in interpreting
the acoustic interactions. In fact, in this study, precise
exclusion criteria have been adopted in order to avoid the
detection of B-lines other than due to HF.
Some authors prefer a subjective overview of the B-li-
nes, not a precise counting, and the choice of the probe can
also be controversial. By now, these limitations have been
deeply investigated [33, 34]. The integration of LUS with a
comprehensive multi-organ ultrasound evaluation is
mandatory to avoid common pitfalls and misdiagnosis, as
recently reviewed by Blanco and Volpicelli [35].
Conclusions
The results of this study confirm the potential of LUS in
tailoring diuretic therapy and speeding up the discharge
time in HF hospitalization. The study stresses the real need
for appropriate timing and modality of LUS in Internal
Medicine. Until the technique comes into common use in
different departments, it is plausible that LUS will evolve
with different facets and needs accordingly.
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